December 21, 2012

Immunomedics Announces New Patent for Antibodies Targeting CD19

December 12, 2012

Immunomedics Develops New Bispecific Antibodies That Exhibit Potent Anti-Lymphoma Activity

December 11, 2012

Immunomedics Provides Clinical Updates on Subcutaneous Injections of Veltuzumab in Autoimmune Disease and Cancer

December 11, 2012

Immunomedics Reports Updated Clinical Results on Potential New Treatment Regimens for Non-Hodgkin Lymphoma

December 10, 2012

Addition of Epratuzumab to Combination Chemotherapy May be Beneficial in Acute Lymphocytic Leukemia

December 10, 2012

Epratuzumab's B-Cell Modulation Effect Elucidated in Preclinical Study

December 6, 2012

Immunomedics to Present at Oppenheimer 23rd Annual Healthcare Conference

December 5, 2012

Immunomedics Announces Outcome of 2012 Annual Meeting of Stockholders

December 5, 2012

Immunomedics Develops Novel Bispecific Antibodies for Diverse Solid Cancers

November 13, 2012

Lupus Patients Treated With Epratuzumab Report Improvements in Health-Related Quality of Life

November 12, 2012

Long-Term Efficacy and Safety Results of Epratuzumab in Lupus Presented at Rheumatology Conference

November 9, 2012

Immunomedics Named Edison Patent Award Winner in Biotechnology by Research & Development Council of New Jersey

November 8, 2012

Immunomedics Announces First Quarter Fiscal 2013 Results and Clinical Program Developments

November 5, 2012

Immunomedics Reports Potential Product Advances at the 2012 Annual Meeting of the American Society of Hematology

November 1, 2012

Immunomedics to participate in the Brean Capital 2012 Life Sciences Summit

October 26,2012

Immunomedics Announces Conference Call and Webcast for First Quarter Fiscal 2013 Financial Results

October 9,2012

Immunomedics Discovers Potential New Therapy for Graft-Versus-Host Disease

September 13, 2012

Immunomedics to Present at 2012 UBS Global Life Sciences Conference

August 23, 2012

Immunomedics Announces Fiscal 2012 Results

August 10, 2012

Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2012 Financial Results

August 7, 2012

Immunomedics to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference

July 24, 2012

Karolinska Institutet and Immunomedics Develop New Anti-HIV Drug

June 14, 2012

Immunomedics to Present at 2012 Wells Fargo Securities Healthcare Conference

June 13, 2012

Immunomedics Reports Updated Results From Phase I Pretargeting Therapy Study in Colorectal Cancer

June 13, 2012

Immunomedics Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma

June 11, 2012

Immunomedics Reports Development of a New Labeling Kit for Attaching Fluorine-18 to Peptides and Temperature-Sensitive Biomolecules, Including Antibodies

June 8, 2012

Epratuzumab Results in Lupus Presented at 2012 Annual European Congress of Rheumatology

June 5, 2012

Immunomedics Announces Results From 3 Clinical Trials Will be Presented at the 59th Annual Meeting of the Society of Nuclear Medicine

June 4, 2012

Immunomedics Reports Final Survival Data From Two-Part Pancreatic Cancer Study With Yttrium-90-Labeled Clivatuzumab Tetraxetan Combined With Gemcitabine

May 29, 2012

Immunomedics to Present at Jefferies 2012 Global Healthcare Conference

May 25, 2012

Immunomedics to Present Final Results of Pancreatic Cancer Study With Clivatuzumab at 2012 Annual Meeting of the American Society of Clinical Oncology

May 10, 2012

Immunomedics to Present at Bank of America Merrill Lynch 2012 Health Care Conference

May 8, 2012

Immunomedics Announces Third Quarter Fiscal 2012 Results and Clinical Program Developments

May 1, 2012

Immunomedics Awarded New Patent for Pretargeted Imaging and Therapy of Cancer With Bispecific Antibody

April 3, 2012

Immunomedics Develops Novel Agents Targeting Renal Cell Carcinoma

April 2, 2012

Immunomedics Develops Bispecific Hexavalent Antibodies for Diverse Epithelial Cancers

April 2, 2012

Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal Cancer

March 26, 2012

Immunomedics To Report Progress With Novel DNL Agents Targeting Solid Tumors At Cancer Conference

March 7, 2012

Immunomedics Appoints Marcella Locastro To Board Of Directors

February 22, 2012

Immunomedics To Present at Upcoming Healthcare Conferences

February 8, 2012

Immunomedics Announces Second Quarter Fiscal 2012 Results and Clinical Program Developments

January 31, 2012

Immunomedics Awarded Broad Patent For ANTI-CD20 And ANTI-CD22 Combination Therapy

January 20, 2012

Immunomedics Reports Final Results From Phase Ib/II Study of Y-90-labeled Clivatuzumab Tetraxetan in Advanced Pancreatic Cancer

January 18, 2012

Immunomedics Reports Clivatuzumab-Based Blood Test Highly Sensitive And Specific For Early-Stage Pancreatic Cancer

January 12, 2012

Immunomedics Announces Presentations At Gastrointestinal Cancers Symposium Showcasing Advances In Pancreatic Cancer Diagnosis And Therapy.